Dexcom Announces FDA Approval of G5 Mobile App for Android Devices

FINALLY!!!!!!

Rejoice Android users..... rejoice!

from Dexcom.com

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM) the leader in continuous glucose monitoring (CGM) for people with diabetes, is pleased to announce the Food and Drug Administration (FDA) approval of the Dexcom G5 mobile app for Android devices. Beginning in June, Android users will have access to the free app for the Dexcom G5 Mobile CGM System, allowing people with diabetes to view and monitor their glucose levels on their mobile devices to manage their diabetes in real time. The Dexcom G5 Mobile CGM System is the first and only CGM platform available for Android in the United States, complementing the 2015 iOS launch.

Download for free at the Google Play store here: bit.ly/AndroidDexcomG5MobileApp

The Dexcom G5 Mobile is a compact CGM system that works to display real-time glucose activity on certain approved display devices. The launch of Dexcom G5 Mobile for Android allows people to manage their diabetes in a more personal and discrete way by providing glucose data on their Android mobile device, as well as the ability to share it safely and conveniently. This empowers them to make informed and timely decisions about their diabetes, resulting in better health outcomes.

"Providing Android users with access to the Dexcom G5 Mobile CGM System has been a priority for Dexcom," said Kevin Sayer, President and CEO, Dexcom. "The new Android app has been thoughtfully designed with customer needs and feedback in mind. It focuses on delivering technology that empowers users by putting critical glucose information on their phones and is compatible with the most popular Android devices currently in the market."

Once commercially available, the new app will make the Dexcom G5 Mobile available on millions of additional phones in the United States. The Dexcom G5 Mobile app for Android will initially be available on several Android devices from Samsung, Motorola and LG, as well as Android Wear watches.

A current list of compatible devices can be found at www.dexcom.com/compatibility.

The Juicebox Podcast is featured on iTunes!

A huge thank you to Apple Podcasts and iTunes for shining a spotlight on episode #111 of the Juicebox Podcast. 

Guest: Actor from 'Baby Daddy' and life-long type 1, Derek Theler...

View fullsize

You can listen to this and past episodes on Apple Podcast. Subscribe today!

Medicare Announces Criteria Covering Dexcom G5 Mobile CGM for All People with Diabetes

press release

March 24, 2017

Medicare Announces Criteria Covering Dexcom G5 Mobile CGM for All People with Diabetes on Intensive Insulin Therapy

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ:DXCM), the leader in continuous glucose monitoring (CGM) for people with diabetes, is pleased to announce that the U.S. Centers for Medicare & Medicaid Services (CMS) has published an article clarifying criteria for coverage and coding of the Dexcom G5 Mobile system, the only therapeutic CGM under this CMS classification. People covered by Medicarewho have either Type 1 or Type 2 diabetes and intensively manage their insulin will now be able to obtain reimbursement.

"This is a new era and a huge win for people with diabetes on Medicare who can benefit from therapeutic CGM," said Kevin Sayer, President and Chief Executive Officer, Dexcom. "This decision supports the emerging consensus that CGM is the standard of care for any patient on intensive insulin therapy, regardless of age."

According to CMS, therapeutic CGM may be covered by Medicare when all of the following criteria are met:

• The beneficiary has diabetes mellitus; and,
• The beneficiary has been using a home blood glucose monitor (BGM) and performing frequent (four or more times a day) BGM testing; and,
• The beneficiary is insulin-treated with multiple daily injections (MDI) of insulin or a continuous subcutaneous insulin infusion (CSII) pump; and,
• The patient's insulin treatment regimen requires frequent adjustment by the beneficiary on the basis of therapeutic CGM testing results.

In order to be included in this category, the system must be defined as therapeutic CGM, meaning you can make treatment decisions using the device. Dexcom G5 Mobile is the only system approved by the FDA to meet that criteria.

The entire release can be found here

---

Decision Moves Continuous Glucose Monitors One Step Closer to Medicare Coverage

great news from JDRF.org !!

January 12, 2017

Continuous glucose monitoring (CGM) devices approved by the FDA for use in making diabetes treatment decisions are durable medical equipment, according to a decision today by the Centers for Medicare & Medicaid Services (CMS). That determination removed a major roadblock to the devices’ coverage under Medicare. Today’s decisions mean that CGMs approved by the FDA for use in making diabetes treatment decisions are eligible for reimbursement under Medicare.

Today’s decision creates a pathway for Medicare coverage for the devices that will bring the nation’s largest insurer in line with the vast majority of the country’s private payers. Although the significant benefits of CGM use have been known since 2008, CMS had previously refused to consider covering the devices under Medicare, saying they did not meet the statutory definitions of durable medical equipment or any other category the agency could cover. Today’s decision removes that impediment.

“JDRF is encouraged by this decision, which will bring us closer to Medicare coverage for continuous glucose monitors,” said Aaron J. Kowalski, PhD, JDRF’s Chief Mission Officer. “I want to thank the tireless JDRF advocates and Congressional champions who have made this progress possible.”

the entire press release can be found here on the JDRF website

---

Dexcom G5 Mobile Gains Apple Watch Complications!

Do you know what watch complications are? 

Complications are the newest feature for the Apple Watch app. Dexcom G5 users with an Apple Watch can choose from 4 different watch faces and by just lifting their wrist they can quickly and easily see their glucose level and trend arrow.

“Complications are small visual elements on the watch face that communicate important information to the user. The term complication comes from watch making, where the addition of features added complexity to the watch construction. Complications are visible whenever the user looks at the watch face, and users can customize which complications are displayed. The number of slots available for complications on a given watch face varies, but most support at least two or three complications.”

— Apple Developer Website

Dexcom representatives told me....

View fullsize

click to expand

"We have seen many social media posts indicating that our users have purchased the Apple Watch primarily because Dexcom CGM glucose data is available on the watch. We are excited that this release will allow our users with an Apple Watch even greater convenience for those who want this important information in an easy-to-use and discreet form."

View fullsize

click to expand

"Close collaboration took place with Apple to get the watch platform to support our use case of 288 updates/day to make this feature possible for CGM. The Dexcom Watch Face was shown at last year’s World Wide Developers Conference in September, and its currently being promoted on Apple’s website in two locations, (1) on great new features of watchOS3, and (2) third-party ecosystems that make the Apple Watch great. Below are screenshots from both of Apple’s website locations."

View fullsize

click to expand

"As part of Dexcom’s commitment of continuous improvement in the quality and user experience of our apps, the 1.6 release also includes several sustaining improvements and enhancements."

Dexcom apps are available for iOS here. 

Click here to learn more about Dexcom

Dexcom G5 App v1.6 and Apple Watch running watchOS 3 or later required. US only.

---